Page 1640 - Williams Hematology ( PDFDrive )

1614 Part XI: Malignant Lymphoid Diseases Chapter 97: Hodgkin Lymphoma 1615

TABLE 97–5. Selected Randomized Clinical Therapeutic Trials in Hodgkin Lymphoma
Study (Number of Patients) Treatment Failure-Free Survival (%) Overall Survival (%) Followup (Years)
LIMITED STAGE, FAVORABLE AND UNFAVORABLE
Milan (140) 149 4 ABVD + IFRT 94 94 12
4 ABVD + STLI 93 96
p = NS p = NS
NCIC-ECOG (405) 155 STLI 92 87 12
4–6 ABVD 87 94
p = 0.006 p = NS
LIMITED STAGE, FAVORABLE
EORTC/GELA H9F (783) 156 6 EBVP + 20-IFRT 84 98 4
6 EBVP + 36-IFRT 87 98
6 EBVP 70 98
p ≤ 0.001 p = NS
GHSG HD10 (1370) 278 2 ABVD + 30-IFRT 86 94 8
2 ABVD + 20-IFRT 86 95
4 ABVD + 30-IFRT 87 94
4 ABVD + 20-IFRT 90 95
p = NS p = NS
LIMITED STAGE, UNFAVORABLE
EORTC/GELA H9U (808) 156 6 ABVD + 30-IFRT 91 95 4
4 ABVD + 30-IFRT 87 94
4 BEACOPP + 30-IFRT 90 93
p = NS p = NS
GHSG HD11 (1422) 159 4 ABVD + 30-IFRT 85 94
4 ABVD + 20-IFRT 81* 94
4 BEACOPP + 30-IFRT 87 95
4 BEACOPP+ 20-IFRT 87 95
ADVANCED STAGE
GHSG HD9 (1201) 143 8 COPP/ABVD + RT 64 75 10
8 BEACOPP + RT 70 80
8 BEACOPP + RT 82 86
escalated
p <0.0001 p <0.005
US Intergroup (854) 181 6–8 ABVD 74 88 5
Stanford V 71 88
p = NS p = NS
Italian Intergroup (331) 170 6–8 ABVD 73 84 7
BEACOPP (4 escalated + 4 85 89
standard cycles)
p = 0.004 p = 0.39

ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, pro-
carbazine, prednisone; COPP, cyclophosphamide, vincristine, procarbazine, prednisone; EBVP, epirubicin, bleomycin, vinblastine, prednisone;
ECOG, Eastern Cooperative Oncology Group; EORTC, European Organization for the Research and Treatment of Cancer; GELA, Groupe d’Etude
des Lymphomes de l’Adulte; GHSG, German Hodgkin Study Group; IFRT, involved-field radiotherapy; NCIC, National Cancer Institute of Canada;
RT, radiotherapy; STLI, subtotal lymphoid irradiation.
*p = 0.03

Kaushansky_chapter 97_p1603-1624.indd 1615 9/18/15 11:12 PM